Form 4: Exelixis EVP and CFO Christopher J. Senner Reports Stock Transactions

Christopher J. Senner, EVP and CFO of Exelixis, Inc., reports the acquisition and disposition of company stock through option exercise and open market sales.

Summary

• On February 24, 2025, Christopher J. Senner, the EVP and CFO of Exelixis, Inc., engaged in transactions involving the company's common stock.
• Senner exercised options to acquire 29,314 shares at a price of $18.80 per share.
• Simultaneously, Senner sold 29,314 shares at a weighted average price of $36.14, with individual sales ranging from $36.11 to $36.21.
• Following these transactions, Senner directly owns 779,607 shares of Exelixis common stock and indirectly owns 2,723 shares through a 401(k) plan.
• He also holds options to purchase 100,000 shares of common stock.

Sentiment

Score: 5

Explanation: This is a neutral report of stock transactions. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, providing transparency to the market regarding the buying and selling activities of company executives. It's common for executives to exercise stock options and sell a portion of the acquired shares for personal financial management.

Comparison to Industry Standards

• Executive stock transactions are a common occurrence in publicly traded companies, particularly in the biotechnology sector.
• Similar transactions are regularly reported by executives at companies like Amgen, Gilead Sciences, and Biogen.
• The size and frequency of these transactions often depend on the executive's compensation package and the company's stock performance.

Stakeholder Impact

• The transactions may have a minor impact on shareholders, as they reflect insider activity.
• The impact on employees, customers, suppliers, and creditors is likely negligible.

Key Dates